Effect Of Thymosin ?1 On Lymphocyte Subsets In Patients With Decompensated Hepatitis B Cirrhosis

Objective:To observe the status of peripheral blood lymphocyte subsets in patients with decompensated cirrhosis of hepatitis B,and observe the changes of lymphocytes in peripheral blood after the use of thymosin alpha 1,and know the influence of thymosin alpha 1 on immune function of patients,and analyze the factors that cause the imbalance lymphocyte subsets in hepatitis B cirrhosis patients with decompensated.Methods:A total of 106 patients with decompensated hepatitis B cirrhosis who were admitted to The First Affiliated Hospital of Zhengzhou University from October 2015to December 2016 were enrolled and randomly divided into control group and treatment group,with 53 patients in each group,and 20 healthy subjects who underwent physical examination were enrolled as healthy group.The patients in the control group were given comprehensive medical treatment,and those in the treatment group were given thymosin?1 in addition to the comprehensive medical treatment.The number of CD3~+(T lymphocyte),CD4~+(helper T lymphocyte),CD8~+(cytotoxic T lymphocyte)cells,and CD4~+/CD8~+ratio in peripheral blood were measured by flow cytometry before treatment and after 12 weeks of treatment.The percentage of CD19(B cells)and the percentage of NK cells(natural killer cells)were recorded.Changes in liver function related parameters before and after treatment were recorded,and clinical symptoms and adverse reactions were observed.An analysis of variance was used for comparison of continuous data between multiple groups,and the least significant difference t-test was used,for further comparison between any two groups;the independent-samples t test or paired t-test was used for comparison between two groups.The chi-square test was used for comparison of categorical data between groups.Results:1.Before treatment,there was no statistically significant difference in all types of lymphocytes between the treatment group and the control group(P>0.05).In the treatment group and the control group,the peripheral blood lymphocytes were significantly lower than those in the healthy group(P<0.05).Child-Pugh C-level indicators were all lower than B-level,and the differences were statistically significant(P<0.05).2.After 12 weeks of treatment,compared with the control group,the number of CD3~+,CD4~+,and CD8~+cells in the treatment group increased significantly(P<0.05),and the CD4~+/CD8~+,percentage of CD19 cells,and percentage of NK cells increased.P>0.05).After treatment,the ratios of CD3~+,CD4~+,and CD4~+/CD8~+increased significantly(P<0.001),and the percentage of CD8~+and CD19 cells and the percentage of NK cells increased(P>0.05).3.After treatment,the ALT and TBIL in the treatment group were lower than those in the control group,and the ALB was higher than the control group(P>0.05).4.During the course of treatment,there were 2 cases of joint pain and 1 case of rash in the treatment group.No adverse reactions occurred in the control group.There was no significant difference in the incidence of adverse reactions between the two groups(?2=3.087,P=0.079).No serious adverse reactions occurred in all cases.Conclusion:1.The imbalance of the proportion of lymphocyte subgroups in the patients withliver cirrhosis in decompensation period.2.With the increase of Child-Pugh grade,the indexes of lymphocyte subsets in patients with hepatitis B cirrhosis were obviously decreased.3.Thymosin alpha 1 as an immune enhancer can significantly improve the imbalance of lymphocyte subsets in patients with decompensated hepatitis B cirrhosis,and restore the liver function,and the safety is good.